AU2013280875B2 - Phenoxyethyl piperidine compounds - Google Patents

Phenoxyethyl piperidine compounds Download PDF

Info

Publication number
AU2013280875B2
AU2013280875B2 AU2013280875A AU2013280875A AU2013280875B2 AU 2013280875 B2 AU2013280875 B2 AU 2013280875B2 AU 2013280875 A AU2013280875 A AU 2013280875A AU 2013280875 A AU2013280875 A AU 2013280875A AU 2013280875 B2 AU2013280875 B2 AU 2013280875B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
methyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013280875A
Other languages
English (en)
Other versions
AU2013280875A1 (en
Inventor
Matthew Allen Schiffler
Jeremy Schulenburg York
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2013280875A1 publication Critical patent/AU2013280875A1/en
Application granted granted Critical
Publication of AU2013280875B2 publication Critical patent/AU2013280875B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013280875A 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds Active AU2013280875B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US61/665,951 2012-06-29
US201361779099P 2013-03-13 2013-03-13
US61/779,099 2013-03-13
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (2)

Publication Number Publication Date
AU2013280875A1 AU2013280875A1 (en) 2014-12-04
AU2013280875B2 true AU2013280875B2 (en) 2015-09-24

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013280875A Active AU2013280875B2 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Country Status (42)

Country Link
US (2) US8962659B2 (https=)
EP (1) EP2867207B1 (https=)
JP (1) JP6127136B2 (https=)
KR (1) KR101653476B1 (https=)
CN (1) CN104411684B (https=)
AP (1) AP2014008164A0 (https=)
AR (1) AR091429A1 (https=)
AU (1) AU2013280875B2 (https=)
BR (1) BR112014031616B1 (https=)
CA (1) CA2875569C (https=)
CL (1) CL2014003535A1 (https=)
CO (1) CO7151507A2 (https=)
CR (1) CR20140553A (https=)
CY (1) CY1119425T1 (https=)
DK (1) DK2867207T3 (https=)
DO (1) DOP2014000287A (https=)
EA (1) EA024392B1 (https=)
EC (1) ECSP14033267A (https=)
ES (1) ES2644812T3 (https=)
GT (1) GT201400288A (https=)
HR (1) HRP20171515T1 (https=)
HU (1) HUE034425T2 (https=)
IL (1) IL236219A (https=)
JO (1) JO3296B1 (https=)
LT (1) LT2867207T (https=)
MA (1) MA37686B1 (https=)
ME (1) ME02840B (https=)
MX (1) MX345324B (https=)
MY (1) MY173878A (https=)
NZ (1) NZ701933A (https=)
PE (1) PE20150182A1 (https=)
PH (1) PH12015500009B1 (https=)
PL (1) PL2867207T3 (https=)
PT (1) PT2867207T (https=)
RS (1) RS56452B1 (https=)
SG (1) SG11201408641UA (https=)
SI (1) SI2867207T1 (https=)
TN (1) TN2014000501A1 (https=)
TW (1) TWI599561B (https=)
UA (1) UA114325C2 (https=)
WO (1) WO2014004229A1 (https=)
ZA (1) ZA201408632B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
ME02896B (me) 2013-12-17 2018-04-20 Lilly Co Eli Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
TWI768043B (zh) 2017-05-18 2022-06-21 瑞士商愛杜西亞製藥有限公司 N-取代吲哚衍生物
US11839613B2 (en) 2017-05-18 2023-12-12 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
PE20191814A1 (es) 2017-05-18 2019-12-27 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
TW201900179A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
US12240812B2 (en) 2019-01-22 2025-03-04 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250818A1 (en) * 2004-05-04 2005-11-10 Pfizer Inc Ortho substituted aryl or heteroaryl amide compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
CA2478653A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
RU2311409C2 (ru) * 2003-01-10 2007-11-27 Ф.Хоффманн-Ля Рош Аг Производные 2-пиперидона в качестве агонистов простагландина
KR100747401B1 (ko) 2003-09-03 2007-08-08 화이자 인코포레이티드 프로스타글란딘 e2 길항제로서의 페닐 또는 피리딜 아미드 화합물
US20050105732A1 (en) 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
MXPA06011555A (es) * 2004-05-04 2006-12-15 Pfizer Compuestos de metil-aril o heteroaril-amida sustituida.
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
ES2392192T3 (es) 2006-04-24 2012-12-05 Merck Canada Inc. Derivados de indol amida como antagonistas del receptor EP4
WO2007143825A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
EP2565191B1 (en) * 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
JP5536773B2 (ja) 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ep4受容体アンタゴニストとしてのヘテロ環式アミド誘導体
US9457084B2 (en) 2010-02-22 2016-10-04 Raqualia Pharma Inc. Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases
PE20131343A1 (es) * 2010-09-21 2013-11-18 Eisai Randd Man Co Ltd Derivados de acido benzoico
DK2729445T3 (en) * 2011-07-04 2016-01-18 Rottapharm Biotech Srl CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
US9120824B2 (en) * 2011-07-04 2015-09-01 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor agonists
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250818A1 (en) * 2004-05-04 2005-11-10 Pfizer Inc Ortho substituted aryl or heteroaryl amide compounds

Also Published As

Publication number Publication date
LT2867207T (lt) 2017-10-10
US8962659B2 (en) 2015-02-24
US20140005226A1 (en) 2014-01-02
BR112014031616A2 (pt) 2017-06-27
MX345324B (es) 2017-01-25
ZA201408632B (en) 2017-06-28
TWI599561B (zh) 2017-09-21
EP2867207B1 (en) 2017-08-09
TW201412717A (zh) 2014-04-01
CL2014003535A1 (es) 2015-05-08
KR101653476B1 (ko) 2016-09-01
IL236219A0 (en) 2015-02-01
EP2867207A1 (en) 2015-05-06
ME02840B (me) 2018-01-20
PT2867207T (pt) 2017-11-01
DK2867207T3 (en) 2017-09-11
SI2867207T1 (sl) 2017-10-30
ES2644812T3 (es) 2017-11-30
AP2014008164A0 (en) 2014-12-31
JP6127136B2 (ja) 2017-05-10
PE20150182A1 (es) 2015-02-13
HK1203937A1 (en) 2015-11-06
CY1119425T1 (el) 2018-03-07
DOP2014000287A (es) 2015-01-31
EA201492255A1 (ru) 2015-03-31
BR112014031616B1 (pt) 2022-06-21
CN104411684B (zh) 2016-08-24
UA114325C2 (uk) 2017-05-25
EA024392B1 (ru) 2016-09-30
MA37686B1 (fr) 2017-04-28
US9402838B2 (en) 2016-08-02
CA2875569C (en) 2016-04-19
CN104411684A (zh) 2015-03-11
ECSP14033267A (es) 2015-09-30
TN2014000501A1 (en) 2016-03-30
MX2014015953A (es) 2015-07-17
GT201400288A (es) 2015-08-27
MY173878A (en) 2020-02-26
JP2015522018A (ja) 2015-08-03
PL2867207T3 (pl) 2018-01-31
MA37686A1 (fr) 2016-09-30
AR091429A1 (es) 2015-02-04
AU2013280875A1 (en) 2014-12-04
HRP20171515T1 (hr) 2017-11-17
CA2875569A1 (en) 2014-01-03
CR20140553A (es) 2015-02-04
WO2014004229A1 (en) 2014-01-03
IL236219A (en) 2017-12-31
RS56452B1 (sr) 2018-01-31
PH12015500009A1 (en) 2015-03-02
NZ701933A (en) 2017-01-27
SG11201408641UA (en) 2015-01-29
PH12015500009B1 (en) 2020-10-09
US20150126555A1 (en) 2015-05-07
CO7151507A2 (es) 2014-12-29
JO3296B1 (ar) 2018-09-16
HUE034425T2 (en) 2018-02-28
KR20150013893A (ko) 2015-02-05

Similar Documents

Publication Publication Date Title
AU2013280875B2 (en) Phenoxyethyl piperidine compounds
JP6212644B2 (ja) フェノキシエチル環状アミン誘導体およびep4受容体モジュレーターとしてのその活性
JP6148400B2 (ja) フェノキシエチルジヒドロ−1h−イソキノリン化合物
US9000043B2 (en) Phenoxyethoxy compounds
EP2867218A1 (en) Dimethyl-benzoic acid compounds
HK1203937B (en) Phenoxyethyl piperidine compounds
AU2014265762B2 (en) Phenoxyethyl dihydro-1H-isoquinoline compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)